Close Menu

NEW YORK – Viracta Therapeutics said on Monday that based on recent discussions with the US Food and Drug Administration, the company will launch a global registrational trial for nanatinostat and valganciclovir for the treatment of patients with relapsed or refractory Epstein-Barr virus (EBV)-positive lymphoma in the first half of 2021.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.